Anti-Angiogenic Therapies for Children with Cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00056963" target="_blank" >RIV/00216224:14110/10:00056963 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.2174/156800910793357899" target="_blank" >http://dx.doi.org/10.2174/156800910793357899</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/156800910793357899" target="_blank" >10.2174/156800910793357899</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Anti-Angiogenic Therapies for Children with Cancer
Popis výsledku v původním jazyce
Tumor angiogenesis, i.e. the development of neovascularisation in and around solid tumors, plays a key role in the local and distant growth of cancer and anti-angiogenic treatments are now established strategies to treat cancer patients. Specific inhibitors of angiogenesis such as bevacizumab or receptor tyrosine kinase inhibitors targeting VEGFR or PDGFR are now in clinical trials and are being increasingly validated for the treatment of poor prognostic cancers. Other anti-angiogenic strategies such ascilengitide or metronomic chemotherapy (low-dose anti-angiogenic chemotherapy) have been developed to treat certain types of adult cancer. In children, the clinical potential of anti-angiogenic approach is still in an early stage of investigation. Thisreview will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer.
Název v anglickém jazyce
Anti-Angiogenic Therapies for Children with Cancer
Popis výsledku anglicky
Tumor angiogenesis, i.e. the development of neovascularisation in and around solid tumors, plays a key role in the local and distant growth of cancer and anti-angiogenic treatments are now established strategies to treat cancer patients. Specific inhibitors of angiogenesis such as bevacizumab or receptor tyrosine kinase inhibitors targeting VEGFR or PDGFR are now in clinical trials and are being increasingly validated for the treatment of poor prognostic cancers. Other anti-angiogenic strategies such ascilengitide or metronomic chemotherapy (low-dose anti-angiogenic chemotherapy) have been developed to treat certain types of adult cancer. In children, the clinical potential of anti-angiogenic approach is still in an early stage of investigation. Thisreview will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FG - Pediatrie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NR9341" target="_blank" >NR9341: Modulace antineoplastického efektu retinoidů LOX/COX inhibitory na modelu dětských solidních nádorů: in vitro studie</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2010
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Cancer Drug Targets
ISSN
1568-0096
e-ISSN
—
Svazek periodika
10
Číslo periodika v rámci svazku
8
Stát vydavatele periodika
AE - Spojené arabské emiráty
Počet stran výsledku
11
Strana od-do
879-889
Kód UT WoS článku
000285777300011
EID výsledku v databázi Scopus
—